|
|
|
|
|
|
CAD and PVD: Health Advances was asked to help a client identify key competitors in coronary artery and
peripheral vascular diseases. Looking at the client's marketed products and those in development, we outlined clinical
trial attributes necessary to position the client's products favorably from both a physician and payer prospective.
Market Sizing for a Novel Mechanical Thrombus Ablation Device: To create a development strategy for a client
with a novel mechanical thrombus ablation device, Health Advances explored four target indications: DVT, peripheral arterial
disease, hemodialysis clots, and coronary thrombi. Extensive secondary and primary research revealed the unmet needs, referral
patterns, decision-making process and reimbursement environment in each clinical area. This allowed the Health Advances team to
develop a detailed market segmentation and sizing which, along with clinical development considerations, formed the basis for the
strategic plan.
Vascularization in Refractory Angina: Health Advances was asked to assess the unmet needs in induction of vascularization
in refractory angina and to determine the relative enthusiasm among physicians toward procedures inducing mechanical injury compared to
novel angiogenic therapies. Feedback from cardiologists, interventional cardiologists, and cardiac surgeons informed clinical trial criteria
and directed a development plan incorporating both methodologies.
Reformulation of a Beta-Blocker: Health Advances was asked to evaluate the opportunity to enter the large but crowded beta-blocker
market with a once-daily formulation of one of the market-leading compounds. A key issue in positioning our client's product was that the branded
compound was also being launched in a daily formulation. While our client's product would have some modest advantages, understanding formulary and
reimbursement issues was essential in determining the degree to which the proposed advantages would overcome an established brand presence in addition
to competition from lower-priced generics.
Cellular Therapies in Cardiac Indications: A large public company sought to develop a clinical trial development plan for cellular therapies
in cardiac indications. Health Advances used a thorough investigation of relevant cellular therapy literature to assist application prioritization and benchmarking
trial parameters. Extensive interviews with cardiovascular and cell therapy experts were used to determine relevant patient segments for the high-priority indications.
P-Selectin Inhibitor for Vascular Diseases: A start-up company engaged Health Advances to analyze multiple vascular diseases including sickle cell anemia,
deep vein thrombosis, ischemic reperfusion injury, and vascular restenosis for potential applicability of a P-selectin inhibitor. The Health Advances team examined market size,
unmet need, competition, trial feasibility, and the role of P-selectin in disease etiology in order to determine the best development strategy for our client.
|
|
 |
|
|
|
|
